Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
Top Cited Papers
- 31 March 2004
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 40 (5), 689-695
- https://doi.org/10.1016/j.ejca.2003.11.025
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane RegionMolecular and Cellular Biology, 2003
- Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumorsInternational Journal of Cancer, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2002
- Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive MalignanciesJournal of Clinical Oncology, 2002
- c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell VariantLaboratory Investigation, 2002
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene, 2001
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998